Screener
Janux Therapeutics JANX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accrued expenses | 2,015 | 4,627 |
| Deferred revenue | 36,149 | — |
| Operating lease right-of-use assets and liabilities, net | (74) | (11) |
| Net cash provided by (used in) operating activities | 147 | (40,837) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (475) | (844) |
| Purchases of short-term investments | (257,593) | (463,976) |
| Maturities of short-term investments | 227,570 | 125,990 |
Item 1. Financial Statements.
FAQ
- What is Janux Therapeutics's operating cash flow?
- Janux Therapeutics (JANX) reported operating cash flow of $12.48M in Q2 2026.
- How has Janux Therapeutics's operating cash flow changed year-over-year?
- Janux Therapeutics's operating cash flow increased by 152.4% year-over-year, from -$23.81M to $12.48M.
- What is the long-term trend for Janux Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Janux Therapeutics's operating cash flow has grown at a 48.4% compound annual growth rate (CAGR), from -$16.98M to -$82.24M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Janux Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude